Citations

Clear

1727 citation(s) found for "So, Alan".

Drug Monitoring of Antiretroviral Therapy for HIV-1 Infection: Method Validation and Results of a Pilot Study
Moyer, Thomas P. , Temesgen, Zelalem , Enger, Robert, Estes, Lynn L., Charlson, Joel, Oliver, Lawrence K., Wright, Alan J. , Enger, Robert, Charlson, Joel R., Wright, Alan

Mayo Clinic

Clinical Chemistry | January 23, 2020 | Volume: 45 | Issue: 9 | Pages: 1465-1476

10.1093/clinchem/45.9.1465 Get It

Abstract Background: Antiretroviral therapy for HIV-1 infection has become increasingly complex. The availability of new and potent drugs and progress in understanding the pathogenesis of HIV-1 infection have led to the establishment of new treatment paradigms. The varying dosing regimens, associated toxicities, and the potential for drug-drug and food-drug interactions further complicate treatment. This complexity contributes to patient nonadherence. Because clinicians have no tools to monitor adherence or drug-drug interactions and because response requires that therapy exceed the known inhibiting concentration, serum monitoring of antiretroviral therapy may play a role in improving treatment of HIV-1 infection. We report methods to quantify serum concentrations of antiretroviral drugs used to treat HIV-1 infection, precision and interference studies of these methods, and results observed in a pilot evaluation of blood serum concentrations from 12 human subjects. Methods: HPLC offers adequate sensitivity to measure peak or trough serum concentrations of delavirdine, lamivudine, nevirapine, indinavir, nelfinavir, ritonavir, and saquinavir and peak serum concentrations of stavudine, zidovudine, and didanosine with reasonable precision. Results: Peak indinavir serum concentrations in most patients were in the range of 1–10 mg/L, and trough concentrations were in the range of 0.1–0.5 mg/L. Peak stavudine concentrations were in the range of 0.3–1.3 mg/L, and trough concentrations were in the range of 0.1–0.5 mg/L. Peak zidovudine concentrations were in the range of 0.1–1.1 mg/L. Conclusions: Because this was a blood serum concentration-seeking pilot study to evaluate analytic performance, we do not report on the correlation of drug response to blood concentration. However, the concentrations observed in patients are generally consistent with blood concentrations reported from studies of monotherapy.
Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders
Ducharme, Simon , Dols, Annemiek , Laforce, Robert , Devenney, Emma , Kumfor, Fiona , Stock, Jan Van den , Dallaire‐Théroux, Caroline , Seelaar, Harro , Gossink, Flora , Vijverberg, Everard G.B. , Huey, Edward D. , Vandenbulcke, Mathieu , Trieu, Calvin , Onyike, Chiadi U. , Souza, Leonardo Cruz de , Santillo, Alexander , Waldö, Maria Landqvist , Landín-Romero, Ramón , Piguet, Olivier , Kelso, Wendy , Eratne, Dhamidhu , Ikeda, Manabu , Perry, David C. , Pressman, Peter , Vandenberghe, Rik , Mendez, Mario F. , Azuar, Carole, Lévy, Richard, Ber, Isabelle Le , Lerner, Alan J. , Ellajosyula, Ratnavalli , Galimberti, Daniela , Hornberger, Michael , Rosen, Howard J. , Hodges, John R. , Diehl‐Schmid, Janine , Pijnenburg, Yolande A.L. , Galimberti, Daniela , Pijnenburg, Yolande A L , Seelaar, Harro , Vandenberghe, Rik , Laforce, Robert , Masellis, Mario , Caramelli, Paulo , Velakoulis, Dennis , Boeve, Bradley F. , Báez, Sandra , Pasquier, Florence , Scarpini, Elio , Swieten, John C. van

Mayo Clinic

Brain | January 16, 2020 | Volume: 143 | Issue: 6 | Pages: 1632-1650

10.1093/brain/awaa018 | PMID 32129844 Get It

Abstract The behavioural variant of frontotemporal dementia (bvFTD) is a frequent cause of early-onset dementia. The diagnosis of bvFTD remains challenging because of the limited accuracy of neuroimaging in the early disease stages and the absence of molecular biomarkers, and therefore relies predominantly on clinical assessment. BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders. To date, ∼50% of patients with bvFTD receive a prior psychiatric diagnosis, and average diagnostic delay is up to 5–6 years from symptom onset. It is also not uncommon for patients with primary psychiatric disorders to be wrongly diagnosed with bvFTD. The Neuropsychiatric International Consortium for Frontotemporal Dementia was recently established to determine the current best clinical practice and set up an international collaboration to share a common dataset for future research. The goal of the present paper was to review the existing literature on the diagnosis of bvFTD and its differential diagnosis with primary psychiatric disorders to provide consensus recommendations on the clinical assessment. A systematic literature search with a narrative review was performed to determine all bvFTD-related diagnostic evidence for the following topics: bvFTD history taking, psychiatric assessment, clinical scales, physical and neurological examination, bedside cognitive tests, neuropsychological assessment, social cognition, structural neuroimaging, functional neuroimaging, CSF and genetic testing. For each topic, responsible team members proposed a set of minimal requirements, optimal clinical recommendations, and tools requiring further research or those that should be developed. Recommendations were listed if they reached a ≥ 85% expert consensus based on an online survey among all consortium participants. New recommendations include performing at least one formal social cognition test in the standard neuropsychological battery for bvFTD. We emphasize the importance of 3D-T1 brain MRI with a standardized review protocol including validated visual atrophy rating scales, and to consider volumetric analyses if available. We clarify the role of 18F-fluorodeoxyglucose PET for the exclusion of bvFTD when normal, whereas non-specific regional metabolism abnormalities should not be over-interpreted in the case of a psychiatric differential diagnosis. We highlight the potential role of serum or CSF neurofilament light chain to differentiate bvFTD from primary psychiatric disorders. Finally, based on the increasing literature and clinical experience, the consortium determined that screening for C9orf72 mutation should be performed in all possible/probable bvFTD cases or suspected cases with strong psychiatric features.
Randomized Controlled Trial of Mobile Closed-Loop Control
Kovatchev, Boris , Anderson, Stacey M. , Raghinaru, Dan, Kudva, Yogish C. , Laffel, Lori M. , Pinsker, Jordan E. , Buckingham, Bruce A. , Doyle, Francis J. , Brown, Sue A. , Church, Mei Mei , Dadlani, Vikash, Dassau, Eyal , Ekhlaspour, Laya , Forlenza, Gregory P. , Isganaitis, Elvira , Lam, David W. , Lum, John W. , Group, iDCL Study, Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc D. , Ambler-Osborn, Louise, Flint, Emily, Schultz, Alan , Kim, Kenny, Church, Mei Mei, André, Camille , Lam, David W., O’Malley, Grenye , Levister, Camilla, Ogyaadu, Selassie, Simha, Vinaya , McCrady-Spitzer, Shelly , Reid, Corey, Jost, Emily , Berget, Cari , Towers, Lindsey, Buckingham, Bruce, Ekhlaspour, Laya, Hsu, Liana, Loebner, Sarah E., Doyle, Francis J., Campos, Tiffany, Passman, Samantha, Murphy, Carlos, Patibandla, Nandan, Kollman, Craig, Pinsker, Jordan E , Doyle, Francis J , Dassau, Eyal , Ekhlaspour, Laya , Forlenza, Gregory P , Lum, John , Kovatchev, Boris , Buckingham, Bruce , Levy, Carol J. , Wadwa, R Paul , Beck, Roy W. , Group, iDCL Study, Oliveri, Mary Clancy , Church, Mei Mei, Lam, David W., Messer, Laurel H , Buckingham, Bruce, Ekhlaspour, Laya, Doyle, Francis J., Kollman, Craig

Mayo Clinic

Diabetes Care | January 15, 2020 | Volume: 43 | Issue: 3 | Pages: 607-615

10.2337/dc19-1310 | PMID 31937608 Get It

OBJECTIVE Assess the efficacy of inControl AP, a mobile closed-loop control (CLC) system. RESEARCH DESIGN AND METHODS This protocol, NCT02985866, is a 3-month parallel-group, multicenter, randomized unblinded trial designed to compare mobile CLC with sensor-augmented pump (SAP) therapy. Eligibility criteria were type 1 diabetes for at least 1 year, use of insulin pumps for at least 6 months, age ≥14 years, and baseline HbA1c <10.5% (91 mmol/mol). The study was designed to assess two coprimary outcomes: superiority of CLC over SAP in continuous glucose monitor (CGM)–measured time below 3.9 mmol/L and noninferiority in CGM-measured time above 10 mmol/L. RESULTS Between November 2017 and May 2018, 127 participants were randomly assigned 1:1 to CLC (n = 65) versus SAP (n = 62); 125 participants completed the study. CGM time below 3.9 mmol/L was 5.0% at baseline and 2.4% during follow-up in the CLC group vs. 4.7% and 4.0%, respectively, in the SAP group (mean difference −1.7% [95% CI −2.4, −1.0]; P < 0.0001 for superiority). CGM time above 10 mmol/L was 40% at baseline and 34% during follow-up in the CLC group vs. 43% and 39%, respectively, in the SAP group (mean difference −3.0% [95% CI −6.1, 0.1]; P < 0.0001 for noninferiority). One severe hypoglycemic event occurred in the CLC group, which was unrelated to the study device. CONCLUSIONS In meeting its coprimary end points, superiority of CLC over SAP in CGM-measured time below 3.9 mmol/L and noninferiority in CGM-measured time above 10 mmol/L, the study has demonstrated that mobile CLC is feasible and could offer certain usability advantages over embedded systems, provided the connectivity between system components is stable.
Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
Andrews, Jack R. , Karnes, R. Jeffrey , Kwon, Eugene D., Bryce, Alan H. , Bryce, Alan H , Ahmed, Mohamed E.

Mayo Clinic

The Prostate | January 13, 2020 | Volume: 80 | Issue: 5 | Pages: 399-406

10.1002/pros.23954 | PMID 31943289 Get It

AbstractBackgroundOptimal sequencing of systemic therapy in the management for metastatic castration resistant prostate cancer (mCRPC) remains poorly elucidated. The CHAARTED and STAMPEDE studies have proven that early chemotherapy in the hormone‐sensitive setting yields a greater net survival advantage than docetaxel for mCRPC. In a retrospective study, we attempt to investigate the two most common treatment sequences for mCRPC and investigate whether earlier chemotherapy for mCRPC is consequential to survival outcomes.MethodsWe identified 112 patients with mCRPC treated at the Mayo Clinic between 2011 and 2017. We identified two cohorts, 80 patients (group A) received full course docetaxel chemotherapy followed by second generation hormone therapy (2nd gen androgen deprivation therapy [ADT]; Abiraterone or Enzalutamide) and 32 patients (group B) treated with 2nd gen ADT followed by docetaxel. The primary endpoint evaluated was 3‐year cancer‐specific survival.ResultsMean prostate specific antigen at initiation of first treatment was 32.0 in group A and 21.7 in group B (P = .4). Bone metastases were more prevalent in group B (87% vs 58%, P = .01). All other clinicopathologic variables were statistically similar between group A and group B. Three‐year cancer‐specific survival was 87.4% vs 64.1% for group A and group B, respectively (P = .016). We report a univariate hazard ratio of 3.61 (95% CI, 1.74‐9.5, 0 P = .01). Three‐year overall survival was 82.4% and 60.8% for group A and group B, P = .01. These results held true when excluding patients with lymph node only metastasi.ConclusionOur data indicates that sequence of systemic therapy may influence outcomes for mCRPC and that docetaxel should be considered before 2nd generation ADT. Our results support the importance of earlier chemotherapy in the castration resistant state.
Pipeline Embolization Device for Treatment of Extracranial Internal Carotid Artery Pseudoaneurysms: A Multicenter Evaluation of Safety and Efficacy
Gopal, Neethu , Hasan, Tasneem F. , Nourollah-Zadeh, Emad , Vakharia, Kunal , Leacy, Reade De , Burkhardt, Jan‐Karl , Castilla, Leonardo Rangel, Kan, Peter , Boulos, Alan S. , De Leacy, Reade , Akinduro, Oluwaseun O. , Yamamoto, Junichi , Mocco, J , Levy, Elad I. , Tawk, Rabih G. , Burkhardt, Jan‐Karl

Mayo Clinic

Neurosurgery | January 10, 2020 | Volume: 87 | Issue: 4 | Pages: 770-778

10.1093/neuros/nyz548 | PMID 31980826 Get It

Abstract BACKGROUND There is a paucity of literature regarding treatment options for extracranial pseudoaneurysms of the internal carotid artery (ICA). To date, Pipeline Embolization Device (PED; Medtronic Inc) use for the treatment of extracranial pseudoaneurysms of the ICA has only been reported from single-center case series. OBJECTIVE To evaluate the safety and efficacy of PED for the treatment of extracranial ICA pseudoaneurysms. METHODS This is a multicenter retrospective study involving 6 high-volume tertiary academic institutions in the United States. We analyzed patients with extracranial ICA pseudoaneurysms treated with PED between January 1, 2011, and January 1, 2019. Clinical assessment was performed pre- and postintervention using the modified Rankin Scale (mRS) and National Institution of Health Stroke Scale (NIHSS) at a minimum of 4-mo follow-up. RESULTS A total of 28 pseudoaneurysms with a mean diameter of 17.7 mm (range: 4.1-52.5 mm) were treated with PED in 24 patients at 6 participating centers. The mean age was 52.1 yr (17-73) ± 14.3 with 14 females and 10 males. At a mean of 21-mo (range 4-66 mo) follow-up, complete occlusion was achieved in 89% (n = 25/28), with near-complete occlusion (>90% occlusion) in the remainder. There were no periprocedural complications. Postprocedure NIHSS was 0 in 88% (n = 21/24) and 1 in 12% (n = 3/24) of patients, and mRS was 0 in 83% (n = 20/24) and 1 in 17% (n = 4/24) of patients. CONCLUSION The treatment of extracranial ICA pseudoaneurysms with PED is safe and effective in selected patients. Randomized controlled trials and prospective cohort studies are needed to establish the role of flow diversion for ICA pseudoaneurysms.
Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017
Haagsma, Juanita A. , James, Spencer L , Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Lucchesi, Lydia R , Sylte, Dillon O , Adebayo, Oladimeji , Ahmadi, Alireza , Aichour, Miloud Taki Eddine, Alahdab, Fares , Al‐Raddadi, Rajaa , Alsharif, Ubai , Altirkawi, Khalid A , Anjomshoa, Mina, Appiah, Seth Christopher Yaw , Aremu, Olatunde , Arora, Amit , Assadi, Reza , Awasthi, Ashish , Quintanilla, Beatriz Paulina Ayala , Balalla, Shivanthi , Banstola, Amrit , Barker‐Collo, Suzanne , Bärnighausen, Till , Behzadifar, Meysam, Bennett, Derrick , Bhaumik, Soumyadeep , Bhutta, Zulfiqar A , Bijani, Ali , Borges, Guilherme , Borschmann, Rohan , Bose, Dipan, Bražinová, Alexandra, Campuzano, Julio César , Cárdenas, Rosario , Carvalho, Félix , Castañeda-Orjuela, Carlos A , Catalá-López, Ferrán , Choi, Jee-Young Jasmine , Christopher, Devasahayam Jesudas , Crowe, Christopher S. , Dalal, Koustuv , Leo, Diego De, Neve, Jan‐Walter De , Deribe, Kebede , Dessie, Getenet , deVeber, Gabrielle , Dharmaratne, Samath Dhamminda , Doan, Linh Phuong , Driscoll, Tim , El‐Khatib, Ziad , Ellingsen, Christian Lycke , Endries, Aman Yesuf , Faro, André , Fereshtehnejad, Seyed‐Mohammad , Fernandes, Eduarda , Fischer, Florian , Franklin, Richard C. , Fukumoto, Takeshi , Gezae, Kebede Embaye , Gill, Tiffany K, Goulart, Alessandra C. , Grada, Ayman , Guo, Yuming , Haghparast‐Bidgoli, Hassan , Haj‐Mirzaian, Arvin , Haj‐Mirzaian, Arya , Hamadeh, Randah R , Hassen, Hamid Yimam , Havmoeller, Rasmus, Henok, Andualem , Hı́jar, Martha, Hole, Michael K., Rad, Enayatollah Homaie , Hossain, Naznin , Hostiuc, Sorin , Igumbor, Ehimario , Irvani, Seyed Sina Naghibi , Islam, Sheikh Mohammed Shariful , Ivers, Rebecca , Jacobsen, Kathryn H. , Jahanmehr, Nader , Jakovljević, Mihajlo , Jha, Ravi Prakash , Shushtari, Zahra Jorjoran , Jozwiak, Jacek Jerzy , Jürisson, Mikk , Kalani, Rizwan, Kasaeian, Amir , Kelbore, Abraham Getachew , Kengne, André Pascal , Khader, Yousef , Khafaie, Morteza Abdullatif , Khalid, Nauman , Khan, Ejaz Ahmad , Kiadaliri, Ali , Kim, Yun Jin , Kısa, Adnan , Defo, Barthélémy Kuate , Biçer, Burcu Küçük , Kumar, Manasi , Lalloo, Ratilal , Lam, Hilton Y. , Lami, Faris , Leasher, Janet L , Li, Shanshan , Linn, Shai , Lunevičius, Raimundas , Machado, Flávia Ribeiro , Razek, Hassan Magdy Abd El , Razek, Muhammed Magdy Abd El, Mahotra, Narayan Bahadur , Majdán, Marek , Majeed, Azeem , Malekzadeh, Reza, Malik, Manzoor Ahmad , Manda, Ana-Laura, Massenburg, Benjamin B. , Maulik, Pallab K , Meheretu, Hailemariam Abiy Alemu , Mehndiratta, Man Mohan, Mendoza, Walter, Mengesha, Melkamu Merid , Meretoja, Tuomo J , Meretoja, Atte , Miazgowski, Tomasz , Miller, Ted R. , Mini, GK , Мirrakhimov, Erkin М , Moazen, Babak , Mezerji, Naser Mohammad Gholi, Mohammadibakhsh, Roghayeh , Mohammed, Shafiu , Molokhia, Mariam , Monasta, Lorenzo , Mondello, Stefania , Montero-Zamora, Pablo A. , Moodley, Yoshan , Moosazadeh, Mahmood , Moradi, Ghobad , Morawska, Lídia , Velásquez, Ilais Moreno , Moschos, Marilita M. , Mousavi, Seyyed Meysam , Murthy, Srinivas , Musa, Kamarul Imran , Naik, Gurudatta , Nangia, Vinay, Nascimento, Bruno Ramos , Ndwandwe, Duduzile , Negoi, Ionuţ , Nguyen, Son Hoang , Nguyen, Long Hoang , Ningrum, Dina Nur Anggraini , Nirayo, Yirga Legesse, Ofori‐Asenso, Richard , Ogbo, Felix Akpojene , Oladimeji, Olanrewaju , Olagunju, Andrew T , Olagunju, Tinuke O , Orpana, Heather , Otstavnov, Stanislav S , Mahesh, P A , Pakhalé, Smita , Park, Eun‐Kee , Pesudovs, Konrad , Polinder, Suzanne , Prakash, Swayam , Rafay, Anwar, Rafiei, Alireza , Rahimi, Siavash , Rahimi‐Movaghar, Vafa , Rahman, Muhammad Aziz , Kumar, Rajesh , Ramezanzadeh, Kiana, Rawaf, David Laith , Renzaho, André M. N. , Resnikoff, Serge , Roever, Leonardo , Sabde, Yogesh , Saddik, Basema , Salamati, Payman , Salimi, Yahya , Salz, Inbal, Samy, Abdallah M , Sanabria, Juan , Sànchez-Riera, Lídia , Santric-Milicevic, Milena M , Satpathy, Maheswar , Sawhney, Monika, Sawyer, Susan M. , Şaylan, Mete , Schwebel, David C. , Seedat, Soraya , Shaikh, Masood Ali, Shams-Beyranvand, Mehran , Shamsizadeh, Morteza , Sharif-Alhoseini, Mahdi , Sheikh, Aziz , Shigematsu, Mika, Shiri, Rahman , Shiue, Ivy , Silva, João Pedro , Sinha, Dhirendra Narain , Filho, Adauto Martins Soares , Soriano, Joan B. , Soshnikov, Sergey , Soyiri, Ireneous N , Starodubov, Vladimir I., Stein, Dan J. , Sufiyan, Mu’awiyyah Babale , Sunshine, Jacob E. , Sykes, Bryan L. , Tabarés‐Seisdedos, Rafael , Tabb, Karen M. , Tessema, Gizachew Assefa , Thakur, Jarnail Singh , Car, Lorainne Tudor , Uzochukwu, Benjamin, Valdéz, Pascual , Varavikova, Elena A. , Vasconcelos, Ana Maria Nogales , Violante, Francesco Saverio , Waheed, Yasir , Wang, Yuan‐Pang , Wijeratne, Tissa , Yadav, Priyanka , Yano, Yuichiro , Yenesew, Muluken Azage, Yisma, Engida , Younis, Mustafa Z , Zafar, Shamsa , Zaman, Sojib Bin , Zodpey, Sanjay , Hay, Simon I , Mokdad, Ali H. , Vos, Theo , Khubchandani, Jagdish , Padrón‐Monedero, Alicia , Wijeratne, T , Stein, Dan J , Islam, Sheikh Mohammed Shariful , Assadi, Reza , Rahman, Muhammad Aziz , Liu, Zichen, Roberts, Nicholas L S , Ahmed, Muktar Beshir , Alghnam, Suliman Abdullah , Aljunid, Syed Mohamed , Antonio, Carl Abelardo T. , Asayesh, Hamid , Bazargan‐Hejazi, Shahrzad , Bedi, Neeraj , Behzadifar, Masoud , Behzadifar, Meysam, Benjet, Corina L. , Benseñor, Isabela M. , Boufous, Soufiane , Carrero, Juan Jesús , Daryani, Ahmad , Daviţoiu, Dragoş Virgil , Degenhardt, Louisa J , Dolan, Kate A , Dubey, Manisha , Zaki, Maysaa El Sayed , Eskandarieh, Sharareh , Filip, Irina , Gill, Tiffany K. , Gupta, Rahul, Hamidi, Samer , Haro, Josep María , Hassankhani, Hadi , Hendrie, Delia V. , Hı́jar, Martha , Hu, Guoqing , Ilesanmi, Olayinka Stephen , Jayatilleke, Achala Upendra , Jonas, Jost B , Kabir, Ali , Kalani, Rizwan, Khoja, Abdullah T , Kim, Young‐Eun , Kim, Daniel , Koyanagi, Ai , Lansingh, Van Charles , Malta, Déborah Carvalho , Mansournia, Mohammad Alì , Melese, Addisu Dagnaw , Meštrović, Tomislav , Moradi‐Lakeh, Maziar , Morrison, Shane D. , Najafi, Farid , Nguyen, Trang Huyen , Nguyen, Huong Lan Thi , Oh, In‐Hwan , Olivares, Pedro Rufino , Patton, George , Phillips, Michael , Radfar, Amir , Rawaf, Salman , Rezaeian, Shahab , Ronfani, Luca , Roshandel, Gholamreza , Saxena, Sonia , Schneider, Ione Jayce Ceola , Sepanlou, Sadaf Ghajarieh , Shen, Jiabin , Singh, Jasvinder A. , Стародубов, В. И. , Stokes, Mark Andrew , Tehrani‐Banihashemi, Arash , Tran, Khanh Bao , Tran, Bach Xuan , Uthman, Olalekan Abdulrahman , Venketasubramanian, Narayanaswamy , Vlassov, Vasily , Winkler, Andrea Sylvia , Azage, Muluken , YIP, PAUL S. F. , Yonemoto, Naohiro , Yu, Chuanhua , Zaidi, Zoubida , Zamani, Mohammad , Zhao, Yong , Lopez, Alan D , Olagunju, Andrew T , Alahdab, Fares

Mayo Clinic

Injury Prevention | January 9, 2020 | Volume: 26 | Issue: Suppl 2 | Pages: i12-i26

10.1136/injuryprev-2019-043296 | PMID 31915273 Get It

Background The epidemiological transition of non-communicable diseases replacing infectious diseases as the main contributors to disease burden has been well documented in global health literature. Less focus, however, has been given to the relationship between sociodemographic changes and injury. The aim of this study was to examine the association between disability-adjusted life years (DALYs) from injury for 195 countries and territories at different levels along the development spectrum between 1990 and 2017 based on the Global Burden of Disease (GBD) 2017 estimates. Methods Injury mortality was estimated using the GBD mortality database, corrections for garbage coding and CODEm—the cause of death ensemble modelling tool. Morbidity estimation was based on surveys and inpatient and outpatient data sets for 30 cause-of-injury with 47 nature-of-injury categories each. The Socio-demographic Index (SDI) is a composite indicator that includes lagged income per capita, average educational attainment over age 15 years and total fertility rate. Results For many causes of injury, age-standardised DALY rates declined with increasing SDI, although road injury, interpersonal violence and self-harm did not follow this pattern. Particularly for self-harm opposing patterns were observed in regions with similar SDI levels. For road injuries, this effect was less pronounced. Conclusions The overall global pattern is that of declining injury burden with increasing SDI. However, not all injuries follow this pattern, which suggests multiple underlying mechanisms influencing injury DALYs. There is a need for a detailed understanding of these patterns to help to inform national and global efforts to address injury-related health outcomes across the development spectrum.
Comparison of commercial serological tests for detection of Helicobacter pylori antibodies
Kost, Louis J., Haddad, Andrea Paula Kafejian , Zinsmeister, Alan R., Talley, Nicholas J.

Mayo Clinic

Journal of Clinical Microbiology | January 5, 2020 | Volume: 30 | Issue: 12 | Pages: 3146-3150

10.1128/jcm.30.12.3146-3150.1992 | PMID 1452698 Get It

Serological testing for Helicobacter pylori infection is one of the diagnostic methods of choice. Various commercial kits that use different antigens have been developed, but data on their diagnostic accuracy and direct comparisons between the tests are lacking. We aimed to evaluate the sensitivity, specificity, and predictive value of three immunoglobulin G enzyme-linked immunosorbent assay kits: Pylori stat, Helico-G, and Premier H. pylori. Serum samples and gastric biopsy findings from 76 patients were evaluated. We found by using a priori cutoff values that the Pylori stat, Helico-G, and Premier kits had overall sensitivities of 96, 96, and 88%, respectively, and specificities of 94, 86, and 96%, respectively, compared with gastric biopsy findings. For 232 serum samples, the Pylori stat test and a previously validated standard serological assay on which the test was based disagreed in 3% of the cases, while for 76 samples that were tested, Helico-G and a previously validated standard assay on which it was based disagreed in 8% of the cases. The intra- and interassay precision of each of the test kits was high. We conclude that serology based on any of these commercial tests represents a reliable and valid method for the diagnosis of H. pylori whether or not highly purified antigens are used.
Serodiagnosis of Helicobacter pylori: comparison of enzyme-linked immunosorbent assays
Newell, D. G., Ormand, J. E., Carpenter, Herschel A., Wilson, Walter R., Zinsmeister, Alan R., Perez-Perez, G I, Talley, Nicholas J. , Perez-Perez, G I, Blaser, Martin J.

Mayo Clinic

Journal of Clinical Microbiology | January 5, 2020 | Volume: 29 | Issue: 8 | Pages: 1635-1639

10.1128/jcm.29.8.1635-1639.1991 | PMID 1761685 Get It

Enzyme-linked immunosorbent assays (ELISAs) have been developed to diagnose Helicobacter pylori infection. However, the methods are not standardized. We therefore prospectively evaluated the sensitivities and specificities of ELISAs developed in the United States and the United Kingdom in a study population comprising 41 consecutive symptomatic outpatients and 35 volunteers. At endoscopy, multiple biopsies were obtained for histology and culture and stained sections were graded for chronic gastritis, active chronic gastritis, and density of H. pylori. Serum samples were analyzed for H. pylori by ELISA. The first set of assays for immunoglobulin G (IgG) and IgA used a pool of sonicated isolates of H. pylori from five patients in the United States (antigen A). The second set of assays, developed in the United Kingdom, used three different antigens: antigen 1, an acid-extractable surface antigen; antigen 2, an acid-extractable antigen from an aflagellate variant; and antigen 3, a urease-containing fraction. Cutoff scores for positive results were determined a priori on the basis of previous serological studies. There was close agreement between histology and culture. In the study population, 36% of the individuals were H. pylori positive. The diagnostic value of the different ELISAs were highly comparable, and the crude antigens performed as well as the more purified antigens. The antigen A IgG had a sensitivity and specificity of 96 and 94%, respectively; the values for antigen 1 were 93 and 96%, respectively. The antigen A IgA and antigen 3 assays were the least sensitive tests.(ABSTRACT TRUNCATED AT 250 WORDS)
Sex-Specific 99th Percentile Upper Reference Limits for High Sensitivity Cardiac Troponin Assays Derived Using a Universal Sample Bank
Apple, Fred S. , Wu, Alan H.B. , Sandoval, Yader , Sexter, Anne, Love, Sara A., Myers, Gary L., Schulz, Karen , Duh, Show‐Hong, Christenson, Robert H.

Mayo Clinic

Clinical Chemistry | January 2, 2020 | Volume: 66 | Issue: 3 | Pages: 434-444

10.1093/clinchem/hvz029 | PMID 32109298 Get It

Abstract Background How to select healthy reference subjects in deriving 99th percentiles for cardiac troponin assays still needs to be clarified. To assist with global implementation of high sensitivity (hs)-cardiac troponin (cTn) I and hs-cTnT assays in clinical practice, we determined overall and sex-specific 99th percentiles in 9 hs-cTnI and 3 hs-cTnT assays using a universal sample bank (USB). Methods The Universal Sample Bank (USB) comprised healthy subjects, 426 men and 417 women, screened using a health questionnaire. Hemoglobin A1c (>URL 6.5%), NT-proBNP (>URL 125 ng/L) and eGFR (<60 mL/min), were used as surrogate biomarker exclusion criteria along with statin use. 99th percentiles were determined by nonparametric, Harrell--Davis bootstrap, and robust methods. Results Subjects were ages 19 to 91 years, Caucasian 58%, African American 27%, Pacific Islander/Asian 11%, other 4%, Hispanic 8%, and non-Hispanic 92%. The overall and sex-specific 99th percentiles for all assays, before and after exclusions (n = 694), were influenced by the statistical method used, with substantial differences noted between and within both hs-cTnI and hs-cTnT assays. Men had higher 99th percentiles (ng/L) than women. The Roche cTnT and Beckman and Abbott cTnI assays (after exclusions) did not measure cTn values at ≥ the limit of detection in ≥50% women. Conclusions Our findings have important clinical implications in that sex-specific 99th percentiles varied according to the statistical method and hs-cTn assay used, not all assays provided a high enough percentage of measurable concentrations in women to qualify as a hs-assay, and the surrogate exclusion criteria used to define normality tended to lower the 99th percentiles.